Madopar Hbs (Benserazide, Levodopa)

Levodopa is a precursor that crosses the blood‑brain barrier and is converted into dopamine, the neurotransmitter deficient in Parkinson's disease. Benserazide blocks the peripheral enzyme aromatic L‑amino acid decarboxylase, preventing levodopa from being metabolized outside the brain, thereby increasing the amount that reaches central dopaminergic pathways.

The specific dose of Madopar Hbs is individualized by a qualified prescriber based on the patient’s clinical condition, age, and response to therapy. Physicians determine the appropriate strength, frequency, and titration schedule to achieve optimal symptom control while minimizing side effects.

The safety of Madopar Hbs in pregnancy and lactation has not been definitively established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by the treating physician in consultation with the patient.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Madopar Hbs combines levodopa with benserazide, offering higher central availability of levodopa compared with levodopa alone. Compared with dopamine agonists, it generally provides stronger symptom relief but may have a higher incidence of motor complications such as dyskinesia. Choice of therapy depends on disease stage, patient tolerance, and physician preference.

Madopar Hbs tablets should be stored at room temperature, below 25 °C, in the original packaging to protect from moisture and light. Keep the container tightly closed and out of reach of children.

Madopar Hbs is taken orally, usually with a small amount of food to reduce gastrointestinal upset. The tablet should be swallowed whole with water and not crushed or chewed unless specifically instructed by a healthcare professional.

Serious risks include the development of dyskinesia (involuntary movements), hallucinations or other psychiatric disturbances, severe orthostatic hypotension, and rare but life‑threatening reactions such as neuroleptic malignant syndrome or anaphylaxis. Patients should be monitored regularly for these events.

Madopar Hbs is contraindicated in patients with known hypersensitivity to benserazide, levodopa, or any excipients, and in those taking non‑selective MAO inhibitors. Caution is also advised for individuals with severe cardiovascular disease, narrow‑angle glaucoma, or a history of malignant melanoma.